Stockwinners Market Radar for September 19, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:12 EDT Cathie Wood's ARK Investment bought 71K shares of Intellia Therapeutics today

19:03 EDT BeiGene announces NICE recommends BRUKINSA in WM treatment - The company states: "BeiGene announced that England's health technology assessment institute, the National Institute for Health and Care Excellence, NICE, has issued a final appraisal document recommending BRUKINSA for the treatment of Waldenstrom's Macroglobulinemia, WM, in adults who have had at least one treatment, only if bendamustine plus rituximab is also suitable. This decision from NICE marks BRUKINSA as the first and only treatment for WM to be recommended for routine use in England and Wales. The NICE Committee acknowledged the high unmet need for an effective and well tolerated treatment for WM "where current chemoimmunotherapy options can cause severe adverse reactions and the need for frequent hospital visits."

18:46 EDT InnovAge director buys $509.8K in common stock - In a regulatory filing, InnovAge disclosed that its director Thomas Scully bought 100K shares of common stock September 16th in a total transaction size of $509.8K.

17:58 EDT Ivanhoe Electric CEO buys $3.33M in common stock - In a regulatory filing, Ivanhoe Electric disclosed that its CEO Robert Friedland bought 417K shares of common stock in on September 16th in a total transaction size of $3.33M.

17:18 EDT General Dynamics awarded $414.77M Defense Logistics Agency contract modification - General Dynamics has been awarded a maximum $414.77M modification to a five-year base contract with one four-year option period for multiple items used in the Abrams Main Battle Tank, Stryker Family of Vehicles, Light Armored Vehicle Family of Vehicles, Cougar, Buffalo and RG-31. This is a firm-fixed-price, indefinite-delivery/definite-quantity contract. The delivery order end date is Sept. 28, 2029. Using military service is Army. Type of appropriation is fiscal 2022 through 2027 Army working capital funds. The contracting activity is the Defense Logistics Agency Land and Maritime, Columbus, Ohio.

17:05 EDT O2Micro announces receipt of revised proposal to acquire company - O2Micro "announced that it has received a revised preliminary non-binding proposal letter, dated September 19, 2022, from FNOF Precious Honour Limited, Mr. Sterling Du, the Chief Executive Officer and the Chairman of the Board, and Mr. Perry Kuo, the Chief Financial Officer and a director of the Company, to reduce the purchase price for acquiring all of the outstanding ordinary shares of the Company that are not already owned by the Consortium or otherwise rolled over, to $4.90 per ADS. As previously announced, the Board had formed a special committee to evaluate the Proposed Transaction, or any alternative strategic option that the Company may pursue. The Special Committee will continue to evaluate the Proposed Transaction in light of the latest development."

16:33 EDT Patria Investments names incoming CFO Ana Russo - Patria Investments announced that Ms. Ana Russo will join the firm on October 3 as incoming Chief Financial Officer and member of Patria's Management Committee. Mr. Marco Nicola D'Ippolito, who has been serving as Chief Financial Officer since January 2017, will then begin a transition process to transfer oversight of Patria's fund administration, finance, accounting, planning and technology functions to Ms. Russo, with the goal of Ms. Russo fully assuming the role of Chief Financial Officer by January 1, 2023. Mr. D'Ippolito will thereafter assume the role of Chief Corporate Development Officer and allocate his time to develop Patria's organic and inorganic growth strategies, evolving to the leadership of a new business vertical. In addition, he will continue to lead Patria's shareholder relations. To ensure a smooth handover and transition, Ms. Russo and Mr. D'Ippolito will work closely together until the end of the current year.

16:31 EDT Allison Transmission to partner with Anadolu Isuzu on electric trucks/buses - Allison Transmission "announces a strategic joint cooperation agreement with Turkey's leading bus and truck manufacturer Anadolu Isuzu. As a part of this JCA, Allison eGen Power(R) 100S electric axles will be integrated into Anadolu Isuzu's light-duty truck and midibus platforms for refuse, distribution and public transportation applications."

16:22 EDT Ford slips 2.6% after warning Q3 costs would run $1B higher than expected

16:17 EDT Ford sees Q3 EBIT at $1.4B-$1.7B

16:17 EDT Ford affirms FY22 adjusted EBITDA view of $11.5B-$12.5B - The company states: "Ford again affirmed its expectation for full-year 2022 adjusted earnings before interest and taxes of between $11.5B to $12.5B, despite limits on availability of certain parts as well as higher payments made to suppliers to account for the effects of inflation. The supply shortages will result in a higher-than-planned number of "vehicles on wheels" built but remaining in Ford's inventory awaiting needed parts, at the end of the third quarter. The company believes that those vehicles - an anticipated 40,000 to 45,000 of them, largely high-margin trucks and SUVs - will be completed and sold to dealers during the fourth quarter. According to the company, based on recent negotiations, inflation-related supplier costs during the third quarter will run about $1.0B higher than originally expected."

16:10 EDT Cognex jumps 10% to $46.04 after raising Q3 revenue guidance

16:07 EDT Molecular Cancer Therapeutics publishes data on Bicycle Therapeutics' BT8009 - Bicycle Therapeutics announced that an article highlighting preclinical data from BT8009, a Nectin-4 targeting Bicycle Toxin Conjugate, was published in Molecular Cancer Therapeutics. Nicholas Keen, Ph.D., Chief Scientific Officer of Bicycle Therapeutics, says: "Having already announced interim, positive results from our ongoing Phase I trial of BT8009, we are pleased to describe the work leading to its identification and the preclinical studies that support its potential to rapidly diffuse into, and to kill, solid tumor cells. The data published in Molecular Cancer Therapeutics describe BT8009's pre-clinical efficacy in a wide range of cell-derived xenograft and patient-derived xenograft tumor models, with full tumor regression frequently seen in large and small tumors. We look forward to providing additional clinical data on BT8009 later this year."

16:05 EDT Zendesk stockholders approve acquisition - Zendesk announced that its stockholders voted to adopt the Agreement and Plan of Merger whereby Zendesk will be acquired by a consortium led by Hellman & Friedman and Permira for $77.50 per share in cash. Subject to customary closing conditions, the proposed transaction is expected to close in the fourth quarter of this year.

16:01 EDT Hippo to complete 1 for 25 reverse stock split - Hippo Holdings announced that its Board of Directors has unanimously approved a 1-for-25 reverse stock split of the company's common stock. The company's common stock is expected to begin trading on a split-adjusted basis when the markets open on Friday, September 30, 2022, under the existing trading symbol "HIPO".

15:56 EDT Nauticus Robotics Inc trading halted, volatility trading pause

14:02 EDT Uber provides security breach update, says Lapsus$ attacker - Uber Technologies said in an update on its security breach: "While our investigation is still ongoing, we are providing an update on our response to last week's security incident. What happened? An Uber EXT contractor had their account compromised by an attacker. It is likely that the attacker purchased the contractor's Uber corporate password on the dark web, after the contractor's personal device had been infected with malware, exposing those credentials. The attacker then repeatedly tried to log in to the contractor's Uber account...The attacker then posted a message to a company-wide Slack channel, which many of you saw, and reconfigured Uber's OpenDNS to display a graphic image to employees on some internal sites. How did we respond? Our existing security monitoring processes allowed our teams to quickly identify the issue and move to respond. Our top priorities were to make sure the attacker no longer had access to our systems; to ensure user data was secure and that Uber services were not affected; and then to investigate the scope and impact of the incident....We identified any employee accounts that were compromised or potentially compromised and either blocked their access to Uber systems or required a password reset. We disabled many affected or potentially affected internal tools. We rotated keys (effectively resetting access) to many of our internal services. We locked down our codebase, preventing any new code changes...The attacker accessed several internal systems, and our investigation has focused on determining whether there was any material impact...We reviewed our codebase and have not found that the attacker made any changes. We also have not found that the attacker accessed any customer or user data stored by our cloud providers (e.g. AWS S3). It does appear that the attacker downloaded some internal Slack messages, as well as accessed or downloaded information from an internal tool our finance team uses to manage some invoices. We are currently analyzing those downloads...We believe that this attacker (or attackers) are affiliated with a hacking group called Lapsus$, which has been increasingly active over the last year or so."

13:02 EDT Wyndham Hotels says new extended-stay brand achieves 100 hotels signed - Wyndham Hotels & Resorts announces that its new, extended-stay brand operating under the working title "Project ECHO" has achieved 100 hotels signed across the United States. Among the most recent signings for developing new construction Project ECHO hotels are South Bend, Ind.-based Holladay Properties and Miami, Fla.-based Gold Coast Premier Properties. Holladay Properties have 25 Project ECHO hotels signed in the key cities across the Midwest as well as Nashville, Tenn.; Savannah, Ga; and Jacksonville, Fla., and Gold Coast Premier Properties has 10 hotels signed in South Florida and New Jersey.

13:00 EDT New Jersey reports August gaming revenue up 10.1% to $470.7M - On Friday, New Jersey's Division of Gaming Enforcement reported that based upon filings with the Division, total gaming revenue reported by casinos, racetracks, and their partners was $470.7M for August, reflecting a 10.1% increase from $427.7M reported in August 2021. Total casino win for the nine casino hotel properties was $274.0M for August 2022, reflecting growth of 4.4% compared to $262.4M for August 2021. For the month of August, internet gaming win reported by casinos and their partners was $131.4M, reflecting growth of 16.1% compared to $113.2M for the prior period. Sports wagering gross revenue reported by casinos, racetracks, and their partners was $65.3M for August 2022, reflecting a 25.5% increase when compared to $52.0M in the prior period. Publicly traded companies in the casino and betting space include Boyd Gaming (BYD), Caesars (CZR), Churchill Downs (CHDN), DraftKings (DKNG), Flutter Entertainment (PDYPY), Gan Limited (GAN), Las Vegas Sands (LVS), MGM Resorts (MGM), Penn Entertainment (PENN), William Hill (WIMHY) and Wynn Resorts (WYNN). Reference Link

12:43 EDT Sotera Health halted for volatility after dropping 11% on court ruling

12:32 EDT Northrop Grumman selected for U.S. Air Force ABMS DI consortium - Northrop Grumman was selected by the U.S. Department of the Air Force to be a member of its Advanced Battle Management System Digital Infrastructure Consortium. Northrop Grumman is one of the five industry partners named to the consortium to design, develop, and deploy advanced data-centric capabilities for the Air Force and Space Force. The company will apply technical expertise in systems engineering, data management, secure processing and connectivity to shape how data is harnessed by the DAF in coordination with the Joint Force to make faster decisions in the multi-domain battlespace, it said in a statement, adding that the Advanced Battle Management System Digital Infrastructure Consortium will strengthen Joint warfighting to support the Department of Defense's JADC2 concept. "As the Department of the Air Force continues to move ABMS forward, Northrop Grumman's expertise in advanced networking, sensors, software, platform integration, autonomy and manned-unmanned teaming across all domains will continue to support the emerging JADC2 needs of the DOD," said Tim Frei, sector vice president, research and advanced design, Northrop Grumman.

12:19 EDT Northern Lights Acquisition Corp trading halted, volatility trading pause

12:14 EDT Vaccine makers drop after Biden says Covid pandemic is over - Shares of vaccine makers, including Moderna (MRNA), Pfizer (PFE), and BioNTech (BNTX), fell on Monday after President Joe Biden said that the Covid-19 pandemic is over. While appearing on CBS's "60 Minutes" airing on Sunday, Biden said that while "we still have a problem with Covid," he believes that "the pandemic is over." Biden commented that "We're still doing a lot of work on it... but the pandemic is over. If you notice, no one's wearing masks. Everybody seems to be in pretty good shape. And so I think it's changing." The U.S. government still designates Covid-19 a Public Health Emergency and the World Health Organization says it remains a Public Health Emergency of International Concern. In afternoon trading, shares of Moderna dropped nearly 10%, while Pfizer shares (PFE) fell 2% and shares of its German partner BioNTech declined nearly 9%. Additionally, shares of Novavax (NVAX), whose protein-based vaccine was authorized in July, fell nearly 10%.

12:00 EDT Gamco Investors falls -16.2% - Gamco Investors is down -16.2%, or -$3.25 to $16.77.

12:00 EDT Grove Collaborative falls -21.6% - Grove Collaborative is down -21.6%, or -$1.50 to $5.45.

12:00 EDT Nexa Resources rises 10.0% - Nexa Resources is up 10.0%, or 50c to $5.48.

11:30 EDT AutoZone sees up to $100M in LIFO charges in Q1 and Q2 - On the company's Q4 earnings call, AutoZone CFO Jamere Jackson said: "For the quarter, our gross margin was down 73 basis points, driven primarily by the accelerated growth in our commercial business and a 28 basis points headwind stemming from a noncash $15 million LIFO charge. I'd like to address the $15 million LIFO charge we took this past quarter, which came from the exhaustion of our reserve balance that occurred during the quarter. The level set, we went from a $335 million reserve balance in Q4 of last year to 0 in Q4 this year, plus an additional $15 million charge. Said differently, we recognized $350 million in higher costs this past year. Basically, all the reduction in our reserves came from higher inventoriable freight costs. This charge does not show up in our cash flow statement this quarter because the accounting for LIFO will adjust the weighted average cost through the P&L to the last in higher-priced items. In a nutshell, it assumes everything you sold in the quarter was at the last and higher prices. We're still modeling for higher freight costs through the end of the calendar year, which in turn means we are modeling LIFO charges through the first half of the new fiscal year. In the first quarter, we anticipate up to $100 million in LIFO charges, and we're forecasting a similar amount for the second quarter. I will note that if freight costs abate as we expect them to, then we'll see these charges reverse and we'll begin to rebuild a LIFO reserve balance."

11:17 EDT Aurinia announces European Commission approval of LUPKYNIS - Aurinia Pharmaceuticals announced that the European Commission has granted marketing authorization of LUPKYNIS to treat adults with active lupus nephritis, a serious complication of systemic lupus erythematosus. The U.S. Food and Drug Administration approved LUPKYNIS on January 22, 2021, in combination with a background immunosuppressive therapy regimen to treat adult patients with active LN. The centralized marketing authorization is valid in all European Union member states as well as in Iceland, Liechtenstein, Norway and Northern Ireland.

11:05 EDT Red White & Bloom announces restructuring of over C$110M of debentures - Red White & Bloom Brands announced the appointment of Colby De Zen as President and Director of the Company effective immediately and the appointment of Gabriel Bianchi to the Board of directors upon completion of regulatory approvals. The Company further announces that it has restructured the terms of certain outstanding debentures issued by the Company to arm's length lenders in the aggregate principal amounts of $70,040,000 and C$2,120,000 and issued a new convertible debenture in the principal amount of C$17,000,000. The Company has appointed strategic investor and entrepreneur Colby De Zen as President of the Company, effective immediately. Mr. De Zen has completed all the necessary cannabis regulatory licensing procedures and will report directly to the RWB Board of Directors. In this new role at RWB, Mr. De Zen will have overarching responsibility for all aspects of business operations. In addition, and further to the Company's press release dated October 21, 2021, the Company has appointed Mr. Colby De Zen to its Board effective September 19, 2022. He is one of the managing directors of the De Zen Family Office, which has deployed significant capital in the public and private sectors, including real estate, manufacturing, technology, trucking/logistics and cannabis. The Company also announces that Mr. Gabriel Bianchi has agreed to join the Company's Board of directors. Gabriel's appointment shall become effective upon completion of all securities and cannabis regulatory licensing procedures. Mr. Bianchi is a real estate Broker of Record with a 325-person realtor team that completed 4,000 transactions last year. He brings 35 years of extensive real estate experience in retail, commercial, industrial, land acquisitions, land assembly and financing. As a result of the restructuring, the Company issued a series of amended and restated secured debentures as follows: A secured debenture in the principal amount of $25,885,000. Note 1 matures on September 12, 2024. A series of secured debentures, with an aggregate principal amount of $9,505,000. Notes 2A, 2B and 2C mature on September 12, 2024. A secured debenture in the principal amount of C$2,120,000. Note 3 matures on September 12, 2024. A secured promissory note in the principal amount of $5,850,000. Note 4 matures on September 12, 2024. Two secured promissory notes in the aggregate principal amount of $10,800,000 that amend and restate convertible promissory notes previously issued to arm's length lenders by RWB Platinum Vape Inc., a wholly-owned subsidiary of the Company, on October 4, 2021. The Amended PV Notes are convertible into common shares of the Company at a price of $0.15 per share, representing a 67% premium to the closing price on September 16. The Company issued a convertible promissory note in the principal amount of C$17,000,000 to an arm's length lender. All or any part of the outstanding and unpaid principal and interest of the New Note is convertible into common shares of the Company at a price of C$0.20 per share, representing a 67% premium to the closing price on September 16. The proceeds from the New Note will be used to settle pre-existing debt, including principal and interest on outstanding instruments. RWB Florida LLC issued a new secured debenture in the principal amount $18,000,000 to an arm's length third party with a maturity date of February 8, 2024. The new note is secured by RWB Florida LLC and specific real estate assets. Proceeds from the RWB FL Note, along with cash on hand, were used to retire existing RWB Florida LLC debt in the amount of $20.3 million.

10:01 EDT P3 Health Partners Inc trading resumes

10:00 EDT Forge Global falls -11.8% - Forge Global is down -11.8%, or -42c to $3.13.

10:00 EDT Nordic American Tankers rises 7.9% - Nordic American Tankers is up 7.9%, or 24c to $3.35.

10:00 EDT Ampex Corp rises 8.4% - Ampex Corp is up 8.4%, or 70c to $9.00.

09:57 EDT Greenpro Capital launches ESG Digital Asset Exchange - Greenpro Capital announced it had launched the World's first Shariah-Compliant ESG Digital Asset Exchange, Green-X. Greenpro Capital was granted the license to operate such exchange by Malaysia's Labuan Financial Services Authority in April 2022. The launch was officiated by LFSA, International Shariah Research Academy, ESG Global and SME Association of Malaysia. Green-X is expecting at least 10 token issuers to come on board by the end of this year, including Cattle Queen Ranch and Koperasi Bersatu Tenaga Malaysia Berhad.

09:56 EDT P3 Health Partners Inc trading halted, volatility trading pause

09:47 EDT Skeena Resources falls -7.0% - Skeena Resources is down -7.0%, or -35c to $4.65.

09:47 EDT Forge Global falls -9.2% - Forge Global is down -9.2%, or -33c to $3.23.

09:47 EDT SIGNA Sports United rises 6.9% - SIGNA Sports United is up 6.9%, or 37c to $5.75.

09:33 EDT Inpixon enters collaboration agreement with Schauenburg System - Inpixon announced a collaboration agreement with Schauenburg Systems to sell Inpixon's real-time location technologies to mining companies in South Africa. Under the agreement the parties will aim to achieve sales of hundreds of thousands of nanoLOC chips and other core technologies of Inpixon that provide real-time tracking, collision avoidance and proximity applications for the mining industry.

09:24 EDT KnowBe4 confirms receipt of $24 per share proposal from Vista - KnowBe4 confirmed the receipt of a non-binding proposal from Vista Equity Partners to acquire all outstanding shares of the Company for $24 per share in cash. The proposal represents a 39% premium to KnowBe4's closing price on September 16, 2022. The Company's Board of Directors regularly considers opportunities to enhance value for its stockholders. In response to an inquiry from Vista, the Board formed a special committee of the Board, comprised solely of independent directors, to engage with Vista and take other actions that it deems appropriate, with the assistance of independent financial and legal advisors. Consistent with its mandate, and in consultation with its legal and financial advisors, the Special Committee will carefully review the Vista proposal and other potential value creation opportunities to determine the course of action that it believes is in the best interests of KnowBe4 and its stockholders.

09:21 EDT NeuroSense announces peer-reviewed publication of PrimeC Phase IIa ALS study - NeuroSense Therapeutics announced the peer-reviewed publication of Phase IIa clinical data in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration in a paper titled, "Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS." Data in the paper are results from NeuroSense's Phase IIa study of its lead drug candidate, PrimeC, a unique and proprietary combination of two FDA-approved drugs-ciprofloxacin and celecoxib-in the treatment of ALS. Key data from the paper include: Safety: The study met its primary endpoint of safety in a 12-month clinical trial with 15 participants living with ALS. Efficacy and Biomarkers: Exploratory efficacy was evaluated by ALSFRS-R and FVC, and blood samples were taken before and during the study for biomarker analysis. PrimeC showed statistically significant changes in ALS-related biomarkers of serum neuron-derived exosomes such as TDP-43 and LC3 as measured by ExoSORT indicating a positive biological activity. The trial was open-label, comparing the data generated to the PROACT database utilizing propensity matching. Conclusions: This study supports the safety and tolerability of PrimeC in ALS. Biomarker analyses suggest early evidence of a biological effect. Based on the results of this study, NeuroSense commenced PARADIGM, a Phase IIb clinical trial in May 2022. Primary endpoints of the study include assessment of ALS biomarkers, evaluation of clinical efficacy, improvement in quality of life, as well as safety and tolerability. "We are very pleased to have our Phase IIa findings of PrimeC published in a leading ALS journal, as interest in PrimeC continues to grow in the ALS scientific community. Our clinical research and scientific teams are actively presenting at conferences as we engage with patient advocacy groups with the aim of bringing a much needed effective treatment to people suffering from this debilitating disease," stated NeuroSense CEO Alon Ben-Noon.

09:19 EDT Banxa Holdings sells non-core domain names for A$3M - Banxa Holdings announced the sale of three non-core domain names, the proceeds of which will be used to bolster the Company's balance sheet. Banxa will receive AUD$3M from the sale of domain names and website assets coinloft.com.au, buyabitcoin.com.au, and the premium domain bitcoin.com.au to one of Australia's leading cryptocurrency exchanges, Independent Reserve. The domain names were formerly part of Banxa's B2C offering before the Company refocused its business to serve the B2B market several years ago. As part of the sale, which will be settled in the coming two weeks, Banxa will receive AUD$2.25m in cash, and a AUD$0.75m equity stake in Independent Reserve.Further sales from the Company's non-core premium Bitcoin domain name portfolio are expected in the future including Bitcoin.co.uk, Bitcoin.ca, Bitcoin.co.in, Bitcoin.eu, Bitcoin.ie, Bitcoins.mx & Bitcoin.ke.

09:17 EDT Applied Blockchain files registration statement for existing shares - Applied Blockchain announced that on September 16, 2022 it filed a Registration Statement on Form S-1 for the registration of approximately 48.3 million existing shares of Applied Blockchain common stock that are currently unregistered. The registration statement does not include the registration of any new shares of Applied Blockchain common stock. The majority of these shares are held by insiders and partners of Applied Blockchain. These shares were set to become available for sale beginning December 1, 2022 pursuant to Rule 144 under the Securities Act of 1933, as amended, and following the SEC declaring the Form S-1 effective, will be eligible to be sold pursuant to a public registration statement.

09:15 EDT Performance Shipping announces signed commitment letter from Alpha Bank - Performance Shipping announced that it has accepted a commitment letter whereby it intends to enter into an agreement for a new term loan facility of up to $18,250,000.00 with Alpha Bank through a separate wholly-owned subsidiary of the Company. This Facility is subject to the completion of customary closing conditions and the execution of a final loan agreement by the Company and its lenders. Proceeds from the Facility will be used to finance up to 50% of the purchase price of the previously announced vessel the Company has agreed to acquire, the M/T Alpine Amalia, to be renamed P. Aliki. This Facility shall bear interest at the rate of SOFR plus 2.60% per annum. The Facility will be repayable in twenty consecutive quarterly installments of $500,000.00 each, and concurrent with the twentieth quarterly installment, the Company will owe a balloon payment of $8,250,000.00.

09:13 EDT U.S. Dept. of Agriculture selects Gevo's Clmate-Smart Farm to Flight proposal - Gevo announced that the U.S. Department of Agriculture has selected Gevo's Climate-Smart Farm to Flight proposal for funding with an award ceiling of up to $30 million. Gevo's project was one of the 70 projects selected by the USDA under the first pool of the Partnerships for Climate-Smart Commodities funding opportunity totaling $2.8 billion. The project aims to create critical structural climate-smart market incentives for low carbon-intensity corn as well as to accelerate the production of sustainable aviation fuel to reduce the sector's dependency on fossil-based fuels. The project will also focus on the importance of immutable tracking and tracing of the carbon-intensity score starting at the farm production level, through biofuels production, all the way to the sale to an airline company. Gevo plans to accomplish this with further development and implementation of Verity Tracking, a blockchain enabled solutions platform for carbon tracking through the entire business system.

09:10 EDT Getty Images announces redemption of outstanding warrants - Getty Images Holdings announced that the Company will redeem all of the outstanding warrants to purchase shares of the Company's Class A common stock, par value $0.0001 per share, pursuant to the terms of the Warrant Agreement, for a redemption price of $0.01 per Warrant, that remain outstanding at 5:00 p.m. New York City time on October 19, 2022. The Warrants were issued under the Warrant Agreement, dated as of August 4, 2020, between CC Neuberger Principal Holdings II and Continental Stock Transfer & Trust Company as warrant agent, as amended by the Warrant Assumption Agreement, dated as of July 22, 2022, by and among CCNB, the Company, CST and American Stock Transfer & Trust Company. Pursuant to the terms of the Warrant Agreement, Getty Images is entitled to redeem all of the outstanding Warrants for the Redemption Price if the last sales price of the Class A Common Stock is at least $18.00 per share on each of twenty trading days within the thirty (30) trading-day period ending on the third business day prior to the date on which a notice of redemption is given. This share price performance target has been met. At the direction of the Company, the warrant agent is delivering a notice of redemption to each of the registered holders of the outstanding Warrants. In accordance with the Warrant Agreement, upon delivery of the notice of redemption for cash, the Warrants may continue to be exercised by the holders thereof in exchange for payment in cash of the $11.50 per warrant exercise price until 5:00 p.m. New York City time on the Redemption Date. The exercise procedures are described in further detail in the notice of redemption and the election to purchase included therein.

09:07 EDT Cboe Global Markets to further expand S&P 500 Index options suite - Cboe Global Markets announced the continued expansion of its S&P 500 Index, SPX, options suite with additional expirations for SPX Weeklys Tuesday and Thursday options, beginning September 19 and September 28, respectively. Total volume in SPX Tuesday and Thursday options have surpassed 44 million contracts since their launch in second-quarter 2022, reflecting strong customer interest and trading activity. The additional expirations for SPX Tuesday and Thursday options will align with the number of expirations currently available for SPX Monday and Wednesday options, and meet growing customer demand for Cboe's SPX offerings. In addition, Cboe will introduce new Tuesday and Thursday-expiring Mini-S&P 500 Index options beginning October 3 and October 12, respectively. With these changes, both SPX and XSP options will offer expirations every day, going out at least four weeks, enabling traders to express their views with even greater precision. "Cboe's proprietary Weeklys contracts are one of our fastest growing products and with these new listings, we are continuing to build out our world-class S&P 500 options franchise to bring even more product choice and versatility to suit our global customers' diverse trading needs," said Arianne Adams, Senior Vice President and Head of Derivatives and Global Client Services at Cboe Global Markets. "As ultra-short-dated SPX options trading activity hit record levels, these new expirations meet strong retail and institutional client demand for cash-settled options to spread risk across more trading days and manage intraday volatility in the markets with even greater agility and efficiency."

09:04 EDT Advent Technologies in fuel cell supply pact with German State of Brandenburg - Advent Technologies Holdings is pleased to announce the signing of a three-year agreement with the German State of Brandenburg for the supply of methanol-powered fuel cell systems, which will be installed in select critical communication sites in the region. Advent's methanol-powered fuel cell systems will be used as a back-up power source for Brandenburg's BOS digital radio network, replacing the diesel-driven emergency power systems at several sites over the next three years. Germany's old public safety and security infrastructure relied on an outdated analogue radio system for communication. BOS is a digital, encrypted, and secure means of communication. The new BOS network allows first responders and other public safety officials to communicate easily and securely. The BOS network now covers 99.2% of German territory.

09:02 EDT ShockWave Medical initiates all-female coronary IVL study - Shockwave Medical has initiated the first-ever prospective coronary intervention study consisting of all female patients - EMPOWER CAD - to determine whether the positive results from earlier coronary IVL studies with the Shockwave C2 Coronary IVL Catheter, which showed similar safety outcomes across both sexes, can be replicated in an expanded, 'real-world' population of female patients with severely calcified coronary lesions. This prospective, multicenter registry will enroll up to 400 female patients with symptomatic ischemic heart disease in up to 50 investigational centers in the United States and Europe and will include a 3-year follow-up. EMPOWER CAD co-principal investigators Margaret McEntegart, MD, PhD, Director of Complex Percutaneous Coronary Intervention Program at Columbia University Medical Center/New York-Presbyterian Hospital and Alexandra Lansky, MD, FACC, FAHA, FSCAI, FESC, Professor of Medicine, Section of Cardiovascular Medicine and Director, Heart and Vascular Clinical Research Program at Yale University School of Medicine, along with the study's European lead, Nieves Gonzalo, Consultant Interventional Cardiologist at Hospital Clinico San Carlos in Madrid, Spain, announced the study at the Transcatheter Cardiovascular Therapeutics annual scientific symposium of the Cardiovascular Research Foundation in Boston, Mass.

09:01 EDT Dorchester Minerals acquires mineral, royalty, overriding royalty interests - Dorchester Minerals announced that on September 16, 2022, it entered into a non-taxable contribution and exchange agreement with an unrelated third party to acquire mineral, royalty and overriding royalty interests of approximately 2,100 net royalty acres located in 12 counties across New Mexico and Texas. The contributing entity will convey its interest to the Partnership in exchange for 851,423 common limited partnership units of Dorchester Minerals, L.P. The acquisition is expected to close on September 30, 2022, subject to customary closing conditions, with cash received by the Contributor on or after July 1, 2022 being contributed to the Partnership.

08:58 EDT Alligator, Aptevo announce FDA issuance of 'may proceed' notification - Alligator Bioscience and Aptevo Therapeutics announced that the US Food and Drug Administration has issued a "may proceed" notification for the ALG.APV-527 investigational new drug application, allowing the companies to initiate clinical trials evaluating the compound for the treatment of 5T4-expressing tumor antigens in multiple solid tumor types. The companies are moving rapidly to initiate a multi-center Phase 1 trial in the US. ALG.APV-527 is an antibody with dual function: tumor-binding and 4-1BB immunomodulatory agonist effects. This has the potential to be clinically important because 4-1BB has the ability to stimulate the immune cells involved in tumor control, making immune cell stimulation through 4-1BB a particularly compelling target for cancer immunotherapy. Preclinical results, presented at the Society of Immunotherapy Cancer's 2021 Annual Meeting, highlighted the differentiated design of the molecule that minimizes systemic immune activation, allowing for highly efficacious tumor-specific responses as demonstrated by potent activity in in vitro models. The tumor-binding function of ALG.APV-527 targets the 5T4 tumor-associated antigen. 5T4 is a protein expression in multiple solid tumor types and limited expression in normal tissues, making 5T4 a compelling target molecule for cancer therapy.

08:56 EDT CyberArk appoints Peretz Regev as chief product officer - CyberArk announced the appointment of Peretz Regev as chief product officer. Regev brings more than 20 years of senior leadership and product engineering experience to CyberArk. Previously, Regev was vice president of Global Data Science and Engineering at PayPal. Regev also served as the general manager of PayPal Israel. In this role, Regev will oversee the organization's product management, R&D, innovation and technology operations. CyberArk's previous chief product officer Chen Bitan will remain the general manager of CyberArk Israel and will continue to play a role in defining the company direction. In addition, he will take on new responsibilities to manage and develop strategic customer accounts with a focus on EMEA.

08:54 EDT Zentek completes sand erosion testing at NRC, rain erosion testing at AMIL - Zentek has completed sand erosion testing at the National Research Council in Ottawa and rain erosion testing at the Anti-icing Materials International Laboratory in Quebec on Zentek's patent-pending Icephobic Coatings. These results, when taken with the strong performance under accelerated ageing announced March 14, 2022, demonstrate that the company's icephobic technology is durable in adverse conditions for both wind turbine and drone industries, where Zentek is currently maintaining its focus. Summary of overall results to date as reported by the NRC and AMIL: As reported in November 2021, icephobicity tests at the NRC yielded strong and consistent results with an average shear stress of 20 kPa required to passively remove ice accretion. Retesting a year later yielded the same results, demonstrating strong stability. Flight tests in real-world icing conditions demonstrated good performance of Zentek's coating, with results indicating retardation of ice accretion and low adhesion to accreted ice. 1,000 hours of UV exposure, equivalent to two years of UV damage in Canada, slightly increased the ice adhesion properties to 43 kPa, which is still considered to be an effective coating in removing ice. Sand erosion testing demonstrated medium to good performance at a high speed of 540 km/h. Rain erosion testing at AMIL demonstrated good performance at 160 km/h and 320 km/h based on our interpretation, speeds at which the leading edge of wind turbines blade tips are exposed. NRC drone testing demonstrated consistent results of maintaining control of rotor thrust in icing conditions while uncoated blades failed to maintain thrust in the same indoor controlled environment. NRC is preparing for outdoor, real-world environment testing of drone rotor blades with Zentek's icephobic coating this winter. AMIL is testing the performance of Zentek's coating on a small wind turbine in an indoor controlled environment. Zentek has filed a full patent application with the Patent Cooperation Treaty, the international patent office, on August 2nd, 2022, for Nanomaterial-Enhanced Elastomer for Passive Ice Accretion Prevention. The patent application will publish approximately 6 months from the date of filing, marking the beginning of the 12-month national phase for Zentek to apply directly in each country of interest.

08:52 EDT Neurocrine announces it will present data on INGREZZA capsules - Neurocrine Biosciences announced that it will present data demonstrating sustained improvements with long-term INGREZZA capsules treatment in adults with tardive dyskinesia at the Psych Congress 2022 scientific meeting being held September 17-20. Neurocrine Biosciences, the leading neuroscience-focused company in the treatment of TD, will present findings from a post hoc analysis of the 48-week, open-label KINECT 4 study of INGREZZA evaluating treatment response patterns. The analysis, which included treatment completers of KINECT 4, found that the proportion of patients meeting rigorous response criteria increased over time: The proportion of participants who reached a greater than or equal to50 percent Abnormal Involuntary Movement Scale improvement from baseline increased from week 8 to week 48. Of the 40 participants with AIMS greater than or equal to50 percent response at week 8, 95 percent also met this threshold at week 48, demonstrating a sustained response. An increase in proportion of participants that met the rigorous 70 percent or more AIMS improvement from baseline increased from week 8 to week 48 increased from week 8 to week 48, from 50 percent to 92 percent for Clinical Global Impression of Change-Tardive Dyskinesia and 53 percent to 88 percent for Patient Global Impression of Change, respectively. "TD can disrupt many aspects of day-to-day life, and adequate assessment, diagnosis, and continued management of symptoms are of key importance," said Eiry Roberts, MD, Chief Medical Officer at Neurocrine Biosciences. "These data demonstrate that a vast majority of participants taking INGREZZA obtained substantial and sustained TD improvement throughout the study, and the proportion of patients achieving symptom relief increased with continued treatment over time." The most common treatment-emergent adverse events reported in KINECT 4 were urinary tract infection and headache.

08:50 EDT Neogen launches Quantitative Cashew ELISA assay - Neogen Corporation announced that it has released its innovative Veratox VIP assay for the detection of cashew, the second assay in Neogen's new Veratox VIP line of enhanced quantitative ELISA products. The new Veratox VIP for Cashew allergen test demonstrates robust performance across sample types while maintaining the simple testing methodology of the Veratox product line. "As plant-based foods and alternative proteins become more in-demand in the marketplace, it is important that we offer highly sensitive tests that are able to detect even the lowest levels of food allergens in order to protect consumers around the world," said John Adent, Neogen's President and CEO. "Cashew is being used more frequently and in more unique ways than before, and it is important that Neogen offers an easy-to-use and highly sensitive solution for its detection."

08:49 EDT GlobalFoundries joins PHLX Semiconductor Sector Index - GlobalFoundries announced that the company has been added to the PHLX Semiconductor Sector Index, SOS, effective Monday, September 19, 2022. "We are proud to take our place on the Semiconductor Sector Index amongst other leading semiconductor companies," said David Reeder, CFO of GF. "Since our successful public listing on Nasdaq in October 2021, our growth strategy continues to drive a clear demand for, and confidence in, our differentiated solutions and company."

08:47 EDT Prospect Capital announces launch of cash tender offer - Prospect Capital announced that it has commenced a cash tender offer to purchase any and all of the outstanding notes listed below. The Tender Offer will expire at 5:00 p.m., New York City time, on September 23, 2022, or any other date and time to which the Company extends the Tender Offer. The Tender Offer is made pursuant to an Offer to Purchase dated today and related notice of guaranteed delivery, which set forth the terms and conditions of the Tender Offer. The consideration to be paid for each $1,000 principal amount of Notes that are validly tendered and not validly withdrawn on or prior to the Expiration Time is $980.00, plus accrued and unpaid interest on the Notes, if any, from the applicable last interest payment date up to, but not including, the Settlement Date. The Company will purchase any Notes that have been validly tendered at or prior to the Expiration Time and accepted for purchase, subject to all conditions to the Tender Offer having been either satisfied or waived by the Company, promptly following the Expiration Time. Assuming the Tender Offer is not extended, the Company expects that the Tender Offer will settle and payment will be made on September 28, 2022.

08:46 EDT SeaStar appoints Sai Prasad Iyer as VP, medical affairs, clinical development - SeaStar Medical announced the appointment of Dr. Sai Prasad N. Iyer, Ph.D to the position of Vice President, Medical Affairs and Clinical Development at SeaStar Medical, effective September 15, 2022. Dr. Iyer brings 20 years of industry experience and will provide leadership in developing and executing clinical trials, including SeaStar Medical's upcoming pivotal clinical trial of its Selective Cytopheretic Device for the treatment of acute kidney injury in adults. He will also lead the development and execution of the Company's Medical Affairs strategy, including external stakeholder management, communication, patient identification, evidence generation, publications, and medical education. Most recently, Dr. Iyer was the interim Head of Medical Affairs and Field Medical Director at Chinook Therapeutics.

08:44 EDT Tryp Therapeutics appoints Jim O'Neill as CFO - Tryp Therapeutics announced that it has expanded its leadership team with the appointment of Jim O'Neill as its CFO. In his new role, Mr. O'Neill will oversee all aspects of Tryp's finance and accounting organization. The appointment of Mr. O'Neill follows the planned transition of Sid Taubenfeld from interim CFO, to his current role as COO. Most recently, Mr. O'Neill founded and served as president of O'Neill & O'Neill Services Corp. providing financial consulting services including CFO and corporate secretarial services to TSXV and CSE listed companies as well as private businesses. In connection with his appointment, Mr. O'Neill has been granted an aggregate of 500,000 stock options. The Options have an exercise price of $0.17 per share, vest over a period of 36 months and are exercisable until September 15, 2032 and will be governed in accordance with the terms of the Company's stock option plan.

08:41 EDT ToughBuilt announces family of tape measures, chalk reels - ToughBuilt Industries announced the Company's entrance into the global measuring and marking market segment category with a feature-rich family of tape measures and chalk reels.ToughBuilt enters this category with both Imperial and Metric ProBlade Tape Measures, each featuring a triple-coated nylon high-contrast blade, 11ft. standout, and an intuitive Blade Control trigger that brings professionals exceptional command at a touch when in use. These products are anticipated to position ToughBuilt as an immediate standard-bearer in the segment, serving professionals, enthusiasts, and do it your self-customers. The Company's latest products will be made available for purchase from October through a leading US home improvement retailer and across ToughBuilt's growing strategic networks of North American and global trade partners and buying groups, servicing over 15,500 storefronts worldwide.

08:39 EDT Boss Money, UBA partner to expand remittance options to Nigeria - BOSS Money and Africa Global Bank announced a collaboration to expand disbursement options for money transfers from the U.S. to Nigeria. The partnership will enable BOSS Money customers to send U.S. dollars for direct deposit at any of the approximately 20 million United Bank for Africa accounts in Nigeria. Through the partnership, BOSS Money customers will be able to transfer up to US$100 to Nigeria for as little as US$3.99 or transfer up to US$2,999 for as little as US$6.99 when using the BOSS Money or BOSS Calling apps.

08:37 EDT RenovoRx snnounces Angela Gill Nelms joins as COO - RenovoRx announced that Angela Gill Nelms has joined the company as Chief Operating Officer . "Angela is a growth-oriented operational leader with experience in clinical trial management, a proven track record for driving innovation, and building high-functioning teams," said Shaun Bagai, CEO of RenovoRx. "Today, we are laser-focused on advancing our Phase 3 TIGeR-PaC clinical trial, launching our Phase 2/3 clinical trial in extrahepatic cholangiocarcinoma, and expanding our clinical pipeline to fight difficult-to-treat cancers via our innovative therapy platform. Angela is the ideal leader to step in as COO at this pivotal juncture in RenovoRx's dynamic trajectory."

08:35 EDT Whistler Pipeline announces new JV pipeline With Cheniere - WhiteWater Midstream announced that subsidiaries of Whistler Pipeline, and Cheniere Energy, (LNG) have executed agreements to move forward with the construction of the ADCC Pipeline, which is a new joint venture 42-inch pipeline that is expected to extend approximately 43 miles from the terminus of the Whistler Pipeline to Cheniere's Corpus Christi Liquefaction Facility. The ADCC Pipeline has been designed to transport up to 1.7Bcubic feet per day of natural gas, expandable to 2.5 Bcf/d of natural gas, and is expected to be in service in 2024, pending the receipt of customary regulatory and other approvals.The Whistler Pipeline is owned by a consortium including MPLX (MPLX), WhiteWater, and a joint venture between Stonepeak and West Texas Gas.

08:34 EDT Bebuzee completes audit of consolidated financial statements - Bebuzee is pleased to announce that Accell Audit and Compliance, PA, its independent audit firm, has completed its audit of the Company's consolidated financial statements for the periods as of June 30, 2021 and 2022, the Company plans to uplist. The Company also announced that over recent months it has taken steps to consolidate its operations under the Bebuzee Inc. operating company. The consolidations include Bebuzee's Cayman Islands, Bebuzee UK, Bebuzee Ireland and Bebuzee Malta.

08:32 EDT Blue Star Foods extends multi-year supply relationship with Avendra - Blue Star Foods announced that it recently signed a multi-year extension to its multi-year supply contract with privately-held Avendra. The Bid Award Purchase Agreement is effective starting August 2022, and is for purchase and distribution of the Company's Blue Star crab meat branded products.

08:29 EDT Jowell Global enters strategic partnership with So.Di.Co Group - Jowell Global announced it has established strategic partnership with So.Di.Co Group, a company headquartered in Milan, Italy, to promote the sales of its organic and natural personal care products under its own brands and its contracted IP derivative products in China. In addition, Jowell Global and So.Di.Co Group will co-develop OEM and ODM suppliers in China for So.Di.Co Group's new product development and enhanced production capacity mainly for China market.

08:26 EDT EVmo opens new rental facility near LAX Airport - EVmo announced the opening of a new RideShare Rental facility in Manhattan Beach, CA, on the outskirts of the Los Angeles International Airport and close to the dispatch centers for two of the major ride-hailing companies. The new location, which was previously a rental car facility for a national chain, is now the largest of the company's rental locations and can support the rental and maintenance needs of the company's rapidly growing rental fleet. In addition, the new location offers drivers easy access to public transportation, expanded parking, and proximity to multiple major transportation hubs.

08:24 EDT Enphase, Gaslicht.com expand IQ microinverter deployments in Netherlands - Enphase Energy announced that Gaslicht.com is seeing an increase in deployments of residential solar energy systems powered by the Enphase IQ7 family of microinverters. Gaslicht.com's energy platform is growing rapidly with year-over-year growth of more than 20 percent.

08:22 EDT GrafTech suspends operations at Monterrey, Mexico facility - In a regulatory 8-K filing on Friday, the company stated: "On September 15, 2022, inspectors from the State Attorney's Office for the Secretary of Environment of the State of Nuevo Leon, Mexico visited GrafTech Mexico, S.A. de C.V.'s graphite electrode manufacturing facility located in Monterrey, Mexico to inspect GrafTech Mexico's facility and certain of the facility's environmental and operating permits. At the conclusion of the inspection, the inspectors issued GrafTech Mexico a temporary suspension notice. The inspector's notice instructed GrafTech Mexico's graphite electrode manufacturing facility to wind down operations within seven days of the notice. In parallel, the Director of Integral Air Management of the Undersecretary of Climate Change and Air Quality of the Ministry of the Environment determined that, among other things, GrafTech Mexico's operating license was no longer in effect. At this time, the Company is not able to assess how long operations at the manufacturing facility will be temporarily suspended. While the Company strongly disagrees with this course of action, the Company is actively evaluating the notice and the allegations contained therein and the Company intends to work with the authorities to address these allegations and will vigorously defend against these allegations."

08:21 EDT Alerislife announces appointment of Heather Pereira CFO - AlerisLife announced that Heather Pereira has been appointed as Senior Vice President, Chief Financial Officer and Treasurer, effective September 19. Pereira most recently served as Vice President and Corporate Controller of Acushnet Holdings Corp. since May of 2017. Previously, starting in 2004, Ms. Pereira held several roles within the accounting and finance departments of Acushnet Holdings. Ms. Pereira has over 20 years of accounting and finance experience and holds a Master's degree in Accountancy and Masters of Business Administration from Northeastern University and received a Bachelor of Arts degree from Boston College.

08:19 EDT Curaleaf completes majority stake acquisition of Four 20 Pharma - Curaleaf Holdings announced the completion of its agreement to acquire a 55% stake in Four 20 Pharma, a fully EU-GMP & GDP licensed German producer and distributor of medical cannabis. Boris Jordan, Executive Chairman of Curaleaf, stated, "We are pleased to complete the transaction with Four 20 Pharma and I am personally thrilled to welcome Torsten and Thomas to the Curaleaf family. Our early focus on Europe has given Curaleaf a formidable strategic asset and strong foundation in one of the industry's critical global markets. Curaleaf is the only U.S. MSO uniquely positioned to capitalize on the opportunity." With the close of the transaction, Curaleaf has solidified a strategic pathway to acquire complete control of Four 20 Pharma after two years of the commencement of adult-use in Germany, which is slated to begin in early 2024.

08:18 EDT Procept BioRobotics, Providence enter multi-system, national contract - PROCEPT BioRobotics and Providence announced a multi-system, national contract to acquire AquaBeam Robotic Systems. As of June 30, 2022, Providence had seven AquaBeam Robotic Systems installed across California and Texas.

08:16 EDT Medexus says FDA delivers medac second notice of incomplete response - On Friday, September 16, Medexus Pharmaceuticals was informed by medac, licensor of Medexus's commercialization rights to treosulfan, that the U.S. Food and Drug Administration has delivered to medac a second notice of incomplete response regarding medac's new drug application resubmission for treosulfan. The FDA's notice requests further supporting information from medac to complete medac's NDA resubmission but does not require submission of new clinical data. Medexus will provide an update to its shareholders and stakeholders once management knows whether the resubmission has been accepted and is better able to assess the impact of this delay. "While we recognize that the FDA's response timeline has proven longer than anticipated, we are encouraged to see that the Agency remains engaged with medac to find a path towards resubmission," commented Ken d'Entremont, CEO of Medexus. "We continue to seek opportunities to collaborate with medac to the extent permitted by our license agreement in order to support medac in satisfying the FDA's requests and in upholding their responsibility for treosulfan regulatory matters. We are evaluating the potential impact of this delay, including on the timing of a commercial launch in the United States, and we are working with our regulatory and legal advisors to plan accordingly. We firmly believe that treosulfan would make a substantial difference for U.S. patients, as it has in Europe and Canada, and we remain optimistic about the prospect of a treosulfan approval in the United States. We remain focused on delivering strong revenue growth and improved overall performance in our current portfolio of products in both the United States and Canada. We were pleased to announce the strongest fiscal Q1 in our company's history by delivering a record US$23.0 million of revenue and improved operating performance. Overall, our monthly results so far suggest that we are heading towards another strong quarter."

08:15 EDT Executive Network Partnering, Grey Rock announces $1.3B business combination - Grey Rock Investment Partners and Executive Network Partnering announced the entry into a definitive agreement to complete a $1.3B business combination resulting in the formation of publicly traded Granite Ridge Resources, Inc. Luke Brandenberg, future CEO of Granite Ridge, commented, "The Grey Rock Funds delivered outstanding operational and financial results for the first half of 2022, including achieving daily production and Adjusted EBITDA records of approximately 17,563 Boe/d and $183 million, respectively, while adding additional high-quality inventory through the acquisition of approximately $21 million of new oil and gas properties. Subsequent to June 30, 2022, the Grey Rock Funds reduced debt by an approximate additional $42 million and acquired approximately an additional $17 million of new oil and gas assets. These results speak to the high quality of the Grey Rock Funds' team, diverse asset base, and capital efficiency of the non-op strategy. Development activity on the assets within the Grey Rock Funds remains robust, as exhibited by the 15.8 net wells brought online since the beginning of the year and the additional 17.1 net wells currently in the development process. As the Grey Rock Funds look at the remainder of 2022, we anticipate a slight reduction in projected production from the operators drilling the assets of the Grey Rock Funds as some operators, given supply and labor constraints, are delaying bringing wells online. This delay may push approximately 4% to 5% of the planned 2022 production on the assets of the Grey Rock Funds from 2022 into 2023. These results should position Granite Ridge for strong financial performance in 2023 following the completion of the planned Business Combination in the fourth quarter of 2022."

08:14 EDT PowerFleet unveils new brand identity - Powerfleet unveiled its new brand identity. Powerfleet's new brand strategy focuses on being the "People Powered IoT" company, born from the knowledgeable, passionate, empathetic, and customer-centric qualities and values of its global team. As part of the company's brand evolution, the Pointer operating division and Innovation Center in Israel will take on an increased importance globally as the technology incubation hub and proving ground for advanced IoT solutions. The previous Pointer subsidiaries in Latin America and South Africa are all integrating into one global Powerfleet brand and organization.

08:14 EDT Gain Therapeutics presents preclinical data on GT-02287 - Gain Therapeutics announced the presentation of new preclinical data at the International Congress of Parkinson's Disease and Movement Disorders 2022 Annual Meeting in Madrid, Spain, evaluating the neuroprotective effect of Gain's lead 'Structurally Targeted Allosteric Regulator' compound, GT-02287, in preclinical in vitro and in vivo models of Parkinson's disease. The results from these latest in vitro and in vivo studies are consistent with previous data presented by the Company and demonstrate statistically significant, dose-dependent effects of GT-02287, the Company's lead compound for the treatment of Parkinson's disease. First, by protecting against key pathophysiological hallmarks of Parkinson's disease, including neurite and lysosomal pathology, and second, by reducing fine motor skill impairment in mice in conduritol beta-epoxide models designed to mimic the neurodegenerative effects of Parkinson's disease. In a poster presentation on September 17, 2022, entitled "GT-02287, A Brain-penetrant Structurally Targeted Allosteric Regulator of Glucocerebrosidase Shows Evidence of Pharmacological Efficacy in Conduritol beta-epoxide Models of Parkinson's Disease," Gain scientists showcased new preclinical data evaluating the neuroprotective effects of GT-02287 following CBE administration. In the first study, the ability of GT-02287 to neutralize CBE-mediated neurodegeneration was evaluated in rat mesencephalic neurons. In this study, CBE was applied followed by administration of GT-02287 at either 4 or 24 hours post CBE insult at doses of 1 microM or 12.5 microM. Three days following insult with CBE, neuronal cultures were fixed and stained for tyrosine hydroxylase, a marker for dopaminergic neurons. Neuronal survival, neurite network and lysosomal health parameters were all evaluated. The results showed that GT-02287 produced a statistically significant therapeutic effect on both the mesencephalic neurite network and overall lysosomal health, supporting results from earlier preclinical studies showing that enhancement of lysosomal glucocerebrosidase activity by GT-02287 protects against the key pathophysiological hallmarks of Parkinson's disease. In a follow-up behavioral assessment study evaluating the neuroprotective effects of GT-02877 in a mouse CBE/alpha-synuclein model, mice were bilaterally injected with alpha-synuclein preformed fibril into the striatum and administrated daily for fifteen days with the CBE and GT-02287 treatment at doses of 30 mg/kg, 60 mg/kg or 90 mg/kg for fourteen days. Fine motor skills were then assessed and compared to results from vehicle control and untreated animals. At each dose level and in a dose-dependent manner, GT-02287 demonstrated statistically significant improvements in locomotor deficits compared to CBE/alpha-synuclein-injured animals, confirming the neuroprotective benefit observed in vitro in this industry standard Parkinson's disease in vivo locomotor model. Through its proprietary SEE-Tx platform, Gain has identified GT-02287, the Company's lead compound for Parkinson's disease, which has the ability to restore the function of GCase, the misfunction of which is implicated in various neurodegenerative diseases. The compound has been characterized in numerous assays and showed the potential to halt disease progression in Parkinson's patients with GBA1 gene mutations as well as patients whose glucocerebrosidase protein was misfolded due to ageing cellular processes. This work was supported through grants from The Michael J. Fox Foundation and the Silverstein Foundation for Parkinson's with GBA and certain of its findings have been presented by Gain scientists and collaborators at previous medical conferences.

08:11 EDT Revance publishes efficacy/safety profile of DAXXIFY for injection - Revance Therapeutics announced the publication of two peer-reviewed articles in Aesthetic Surgery Journal, the official journal of The Aesthetic Society. The publications reported the impact of DAXXIFY or DaxibotulinumtoxinA-lanm) for injection on brow position and frontalis muscle activity from a post-hoc analysis of patients in the Phase 2a forehead line study and the SAKURA open-label safety study as well as presenting the efficacy and safety of DAXXIFY analyzed by age and race based on a subgroup analysis of the SAKURA glabellar lines clinical trials. "The newly released publications in the Aesthetic Surgery Journal showcase Revance's commitment to generating novel data that helps healthcare providers more fully understand the clinical performance of DAXXIFY ," said Conor Gallagher, PhD, Vice President of Medical Affairs and Scientific Innovation at Revance. "This data demonstrates that treatment of frown lines with DAXXIFY results in an overall positive change in eyebrow position even with a modest reduction in forehead muscle activity."

08:11 EDT Array Technologies launches Array OmniTrack, Array STI H250 - Array Technologies is launching its two newest product offerings, Array OmniTrack and Array STI H250, at RE+ in Anaheim, Calif. from September 19-22. Building on the Company's more than 30-year long history of advanced solar technology, the U.S. launch of Array OmniTrack and Array STI H250 product families expands Array's existing line of DuraTrack products. The three tracker product lines address varying customer requirements and the changing needs of the utility-scale solar industry and meet the IRA's domestic sourcing content requirements. Array's comprehensive product portfolio and track record of innovation provides customers with solutions that meet the requirements and priorities of their site. With these new product introductions, Array continues to deliver reliability, ease of installation, and extreme weather risk mitigation that provide optimal project returns to developers and engineering, procurement, and construction companies.

08:10 EDT LKQ Corp. appoints Varun Laroyia as CEO, LKQ Europe, Rick Galloway as CFO - LKQ Corporation announced the following leadership appointments, effective immediately: Varun Laroyia, Executive Vice President and CFO, has been appointed as CEO and Managing Director of LKQ Europe. Mr. Laroyia succeeds Arnd Franz, who is leaving the Company to join Mahle Group as its CEO, where he spent 18 years prior to joining LKQ Europe. Rick Galloway, CFO of LKQ's Wholesale - North America and Self Service segments, has been appointed as LKQ's Senior Vice President and CFO.

08:09 EDT Ralph Lauren announces long-term targets ahead of investor day - The company said, "Over the next three years, from a base of Fiscal 2022 through Fiscal 2025, the Company expects an acceleration in revenue growth to a compound annual growth rate of mid- to high-single digits in constant currency. Operating profit growth is expected to exceed the rate of top-line growth as a result of continued operating margin expansion. Operating margin is expected to expand to at least 15% by Fiscal 2025 in constant currency, driven by a combination of modest gross margin expansion and operating expense leverage balanced with continued investments in the Company's long-term strategic priorities. In addition, capital expenditures are expected to represent approximately 4% - 5% of revenue annually through Fiscal 2025. The Company expects to continue returning excess free cash flow to shareholders over the next three years, with plans to return approximately $2 billion on a cumulative basis through Fiscal 2025 through its regular quarterly cash dividends and share repurchases, subject to the authorization of its Board of Directors and overall business and market conditions. The Company's Board of Directors increased the regular quarterly cash dividend on the Company's Common Stock by 9% to $0.75 per share at the beginning of Fiscal 2023, representing an annual dividend of $3.00 per share. The Company's current share repurchase authorization enables it to repurchase up to $1.4 billion in shares of Class A Common Stock, subject to overall business and market conditions. The Company's outlook is based on its best assessment of the current macroeconomic environment, including ongoing global supply chain and inflationary pressures, foreign currency volatility, the war in Ukraine, COVID-19 variants and other COVID-related disruptions."

08:08 EDT Inari Medical announces results from U.S. cohort of FLASH Registry - Inari Medical announced outcomes of the fully enrolled 800-patient FLASH registry in pulmonary embolism. The data was presented during a Late-Breaking Clinical Trial session at the 2022 TCT conference on September 18th by Principal Investigator, Catalin Toma, MD, an Interventional Cardiologist at University of Pittsburgh Medical Center. The data was also simultaneously published in EuroIntervention, the official journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions. FLASH is a prospective, multicenter, single-arm registry evaluating real-world patient outcomes after treatment of PE with FlowTriever. The primary endpoint, major adverse events comprising device-related mortality or major bleeding within 48 hours and intraprocedural device or procedure-related acute events, was low at 1.8%. Patients experienced immediate hemodynamic and symptom improvement with modest hospital resource burden, demonstrated by minimal need for adjunctive therapy and a median post procedure ICU stay of 0 days. All-cause mortality was only 0.8% at 30 days.

08:06 EDT Rhythm presents disease burden findings, analyses of setmelanotide data - Rhythm Pharmaceuticals announced the presentation of new findings on the burden of hyperphagia and obesity on patients with Bardet-Biedl syndrome and their caregivers during the 60th Annual Meeting of the European Society for Paediatric Endocrinology held in Rome on Sept. 15 to 17.Rhythm and its collaborators delivered one poster and three oral presentations during ESPE 2022, including data from new analyses that showed setmelanotide achieved substantial weight loss benefit in adolescent and pediatric patients with rare MC4R pathway diseases across three separate pivotal trials. Rhythm's CARE-BBS multi-country survey of adult caregivers of 242 individuals with hyperphagia and severe obesity due to BBS was designed to assess overall global impact and burden of disease on caregivers. CARE-BBS participants at the time of the survey were residents of the United States, Canada, United Kingdom or Germany.At ESPE 2022, Dr. Forsythe delivered an oral presentation entitled, "The Multifaceted Burden Experienced by Caregivers of Individuals with Bardet-Biedl Syndrome: Findings from the CARE-BBS Study," and a poster, "Caregiver Burden in Bardet-Biedl Syndrome: a Survey of Obesity and Hyperphagia Impacts." Together, these presentations highlighted that hyperphagia and obesity associated with BBS places a substantial burden on the lives of patients and their caregivers including their physical and mental health, productivity and social relationships. In addition, the findings illustrate how the negative impact of hyperphagia on caregivers affects family dynamics, emotional well-being, and caregiver employment. Jesus Argente, MD, Professor in the Department of Pediatrics and Pediatric Endocrinology, Universidad Autonoma de Madrid, delivered an oral presentation entitled, "Effects of Setmelanotide Treatment in Children and Adolescents with Proopiomelanocortin Deficiency, Leptin Receptor Deficiency, and Bardet-Biedl Syndrome," on data from post-hoc analyses of Phase 3 data across three pivotal trials. Data in this presentation showed that setmelanotide achieved substantial weight loss benefit in adolescent and pediatric patients ages 6 to 17 years old with severe obesity due to BBS, or POMC or LEPR deficiency. Highlights from the data include: mean reduction of -0.75 in BMI-Z score for patients with BBS; mean reduction of -0.55 in BMI-Z score for patients with LEPR deficiency; and mean reduction of -1.51 in BMI-Z score for patients with POMC deficiency. Dr. Argente also presented a poster entitled, "VENTURE: Design of a Phase 3 Multicenter, 1-Year, Open-label Trial of Setmelanotide in Pediatric Patients Aged 2 to less than6 Years with Rare Genetic Diseases of Obesity." In August 2022, Rhythm announced that it completed enrollment in this trial.

08:03 EDT Takeda Pharmaceutical, Enel North America enter long-term VPPA - Takeda and Enel North America announced the signing of a long-term virtual power purchase agreement, or VPPA, for the electricity delivered to the power grid from a 79 megawatt, or MW, portion of Enel's Seven Cowboy wind project in the state of Oklahoma in the U.S. The agreement, advised by Edison Energy, advances progress towards achieving Takeda's goals of reducing 40 percent of scopes 1 and 2 greenhouse gas, or GHG, emissions by 2025 and achieving net-zero1 GHG emissions for scopes 1 and 2 before 2035.

07:51 EDT Charge Enterprises selected by City Parking for EV charging infrastructure - Charge Enterprises announced the signing of a master service agreement for the strategy, planning and implementation of EV charging infrastructure with City Parking, New York City's largest privately owned parking management provider, with 135 owned and operated locations in the New York City Area.

07:47 EDT Aesther Healthcare files preliminary proxy statement for Ocean Biomedical deal - Aesther Healthcare Acquisition and Ocean Biomedical announced that AHEA has filed with the U.S. Securities and Exchange Commission a preliminary proxy statement in connection with its proposed business combination with Ocean. The combined company will work to accelerate the development of Ocean Biomedical's core assets in oncology, fibrosis, and infectious diseases, all based on new target discoveries enabling first-in-class drug and vaccine candidates - developed through past and ongoing grants totaling $123.9 million. The Preliminary Proxy Statement contains information about the proposed Business Combination, including a business overview, terms of the Transaction, pro-forma financial information and risk factors related to the Transaction. Upon closing of the Transaction, Ocean Biomedical will be a wholly owned subsidiary of Aesther, and Aesther will change its name to Ocean Biomedical, Inc., and its common stock and warrants are expected to be listed on Nasdaq, under the symbols "OCEA" and "OCEAW," respectively. The Transaction is anticipated to provide Ocean with approximately $105 million of cash proceeds to its balance sheet, assuming no redemptions by AEHA's public shareholders. The Transaction includes up to $40 million committed backstop by Vellar Opportunity Fund SPV LLC - Series 3. Aesther has also entered into a Common Stock Purchase Agreement with White Lion Capital LLC, a Nevada limited liability company. The Purchase Agreement provides that White Lion Capital is committed to purchase the Company's Common Stock with an aggregate gross purchase price of up to $75,000,000 from time to time during the commitment period, which starts on the date of the filing of the initial registration statement covering the resale of securities issued under the Purchase Agreement, and shall terminate on the twenty-fourth month anniversary of the filing of such initial registration statement, on terms as specified in the Purchase Agreement. The combined company intends to use the net proceeds from the Transaction for the development, working capital, and supporting the operations of Ocean's assets in oncology, fibrosis, and infectious disease. The proposed Transaction was unanimously approved by the boards of directors of all parties and is expected to be completed in Q4 2022, subject to, among other things, the approval by Aesther stockholders, governmental, regulatory and third party approvals, satisfaction of minimum closing net tangible asset and cash requirements, and the satisfaction or waiver of other customary closing conditions.

07:44 EDT AnPac Bio appeals Nasdaq delisting notice - AnPac Bio-Medical announced that on September 16, 2022, the Company filed a request for a hearing before the NASDAQ Hearings Panel to present its financial data including Shareholders' Equity and plan with the applicable listing requirements. This request was due to a Staff determination letteron September 9, 2022 from the Listing Qualifications Department of The Nasdaq Stock Market notifying the Company of the Staff's determination to delist the Company's securities from The Nasdaq Capital Market due to the Company's failure to regain compliance with the $1 per share bid price requirement of Listed Securities required for continued listing as set forth in Listing Rule 5450(a)(1), following the 180 calendar day compliance period set forth in Listing Rule 5810(c)(3)(A). On September 16, 2022, Company received a letter from Nasdaq granting the appeal and scheduling the Nasdaq Hearings Panel for October 20, 2022. In the meantime, the Company will continue to be listed and its shares will continue to be traded on Nasdaq, pending a final written decision by the Nasdaq Hearings Panel after the October 20, 2022 hearing. On September 9, 2022, the Company received a Staff determination letter from the Listing Qualifications Department of The Nasdaq Stock Market notifying the Company of the Staff's determination to delist the Company's securities from The Nasdaq Capital Market due to its failure to regain compliance with the $1 Bid Rule within the 180 calendar day Compliance Period. Earlier, on March 8, 2022, Nasdaq staff notified the Company that the bid price of its listed security had closed at less than $1 per share over the previous 30 consecutive business days, and, as a result, did not comply with the $1 Bid Rule. In accordance with Listing Rule 5810(c)(3)(A), the Company was provided 180 calendar days, or until September 5, 2022, to regain compliance with the $1 Bid Rule. Since then, the Company has not regained compliance with the $1 Bid Rule, and Nasdaq staff believes that the Company is not eligible for a second 180 day Compliance Period because Nasdaq staff believes that the Company has not demonstrated compliance with the minimum $5,000,000 Shareholders' Equity initial listing requirement for The Nasdaq Capital Market. Nasdaq had written to the Company earlier that if Company has a Shareholders' Equity above $5,000,000, it may obtain another 180 day period. At the October 20, 2022 hearing, the Company intends to present its financial data including Shareholders' Equity and its plan to regain compliance with $1 Bid Rule to seek a second 180 day period. There can be no assurance that the Panel will grant the Company's request for a suspension of delisting or continued listing, even if the Company's financial data evidences sufficient Shareholders' Equity.

07:41 EDT Trees Corporation to acquire assets of Green Tree in cash, stock transaction - TREES has signed definitive documents to acquire the Green Tree Longmont and Green Tree Berthoud dispensaries in the state of Colorado, over 34,000 square feet of grow operations, and a state of the art manufacturing facility. This acquisition will add to the Company's current footprint in Colorado and will bring its total number of Colorado dispensaries to 4 along with 3 operational stores in Oregon, for a total of 7 retail dispensaries. The acquisition is expected to generate more than $10M of revenue with strong EBITDA margins within the TREES platform. Trees will acquire Green Tree for a combination of cash and stock. The Company is in the process of submitting the change of ownership application with the Colorado Marijuana Enforcement Division for all of the assets to be acquired, and expects the acquisition to close in the fourth quarter of 2022. When the transaction closes, the senior leadership of Green Tree will become an important part of the Trees team. Allyson Feiler, the founder of Green Tree, will become a member of the Trees Board of Directors and join the executive management team as Chief Marketing Officer. Loree Schwartz, Owner, CFO and Head of Compliance of Green Tree, will also join the Trees executive team as Chief Compliance Officer.

07:37 EDT Horizon Partners calls TransGlobe statements 'desperate, false' - Horizon said, "Horizon Partners, a privately-owned firm that manages the Horizon Absolute Return Fund Limited, which is a shareholder of TransGlobe Energy Corporation (TGA), issued a public statement responding to the desperate and false statements made by TransGlobe in its September 16, 2022, press release. Horizon repeats its call for all shareholders of TransGlobe to VOTE AGAINST the proposed plan of arrangement pursuant to which Vaalco Energy (EGY) would acquire all of the issued and outstanding common shares of TransGlobe in a stock-for-stock business combination transaction . The Proposed Transaction will be considered at a special meeting of the Company currently scheduled to take place on September 29, 2022... At the time the Proposed Transaction was announced, Horizon communicated its concerns based on its evaluation of the Proposed Transaction to TransGlobe management and the Chairman of the Board. The response received was that Horizon's concerns would be addressed in future disclosure, including in the management information circular to be issued in connection with the Proposed Transaction. However, none of these concerns were addressed. At the time of the publication of our first press release, we reached out to management and made ourselves available to discuss our views, but management has failed to respond. Horizon had expected that the Board of Directors would exercise its duties to act in the best interests of the Company and seriously consider and address the legitimate concerns and alternative views expressed by its shareholders, however the Board has instead chosen to use its efforts to label such views as "spurious" and questioning motives unfairly and without basis, accusing us of pursuing selfish "short-term objectives" and "misrepresenting the transaction". Clearly, our only objective is to maximize shareholder value for ourselves and all of our fellow TransGlobe shareholders...In summary, TransGlobe's failed attempt to discredit Horizon's analysis focused its criticisms on tangential elements of the analysis, but failed to address the primary concern of Horizon and the fellow shareholders that have contacted us, namely, that the current terms of the Proposed Transaction severely undervalue TransGlobe given that the Company is in a position to monetize value in the next 12 months that equals or exceeds the USD 231 million consideration offered to TransGlobe shareholders in the Proposed Transaction, while keeping its full stake in its core Egyptian business..Horizon thanks its fellow shareholders for the tremendous support we have received to date and urges all TransGlobe shareholders who have not done so already to VOTE AGAINST the Proposed Transaction AS SOON AS POSSIBLE."

07:34 EDT Rocket Lab to launch dedicated Electron mission for GA-EMS - Rocket Lab announced that it will launch a dedicated Electron mission for General Atomics Electromagnetic Systems, or GA-EMS. Electron is scheduled to launch the "It Argos Up From Here" mission from Rocket Lab Launch Complex 1 in Mahia, New Zealand during a launch window that opens October 5. The "It Argos Up From Here" mission will launch the GA-EMS designed and manufactured satellite carrying the A-DCS hosted payload. The A-DCS mission is supported by the National Oceanic and Atmospheric Administration, or NOAA, Cooperative Data and Rescue Services Program, which arranged the launch through the Hosted Payload Solutions contract vehicle administered by the U.S. Space Force's Space Systems Command.

07:32 EDT Quipt Home Medical announces closing of upsized senior credit facilities - Quipt Home Medical announced the closing of $110,000,000 in senior secured credit facilities with CIT Bank, a division of First-Citizens Bank & Trust Company. The senior secured credit facilities are in the aggregate amount of $110,000,000 (comprised of a term loan facility in an aggregate principal amount of $5,000,000, a delayed draw term loan facility in an aggregate principal amount of $85,000,000 and a revolving credit facility in an aggregate principal amount of $20,000,000. The Company originally announced this transaction on August 15, 2022 when it executed a binding commitment letter with CIT for up to $80,000,000 in Senior Credit Facilities. However, as a result of strong demand from CIT and its syndicate of lenders the Senior Credit Facilities were increased. The Senior Credit Facilities are evidenced by an Amended and Restated Credit and Guaranty Agreement, which amend and restate the original Credit Agreement dated September 18, 2020 between Quipt and CIT. The primary use of proceeds of any loans made under the Senior Credit Facilities will be to finance potential future acquisitions and general working capital purposes.

07:30 EDT Kinross Gold commits to $300M in share buybacks over remainder of 2022 - Kinross Gold Corporation is pleased to announce that it is launching a new, enhanced share buyback program. The Company's Board of Directors and management believe Kinross' shares offer the best return available on shareholders' capital and therefore have decided to allocate a more substantial portion of cash available to share buybacks to enhance per-share metrics and improve shareholder returns. This announcement follows constructive discussions with Elliott Investment Management as well as a number of the Company's other shareholders. Elliott is supportive of the enhanced buyback program, which is designed to achieve a shared objective of unlocking value for shareholders. The strength of Kinross' business coupled with its investment grade balance sheet allow it to allocate additional funds to share buybacks while also reinvesting in its business and maintaining a strong credit profile. The Company is maintaining its quarterly dividend. Key elements of the enhanced buyback program: Under the new program Kinross will: Buy back $300 million in shares over the remainder of 2022. In 2023 and 2024, allocate 75% of its excess cash to share buybacks. Kinross' approach to the enhanced buyback program will ensure the buyback is affordable and sustainable, protecting Kinross' strong balance sheet and capacity to continue investing in its business. Buybacks in 2023 and 2024 will only take place if net leverage is below the current LTM net leverage ratio of 1.7:1. In addition, the Company would intend to temporarily pause buybacks in case of a ratings downgrade, major operational disruptions or a significant drop in gold price.

07:25 EDT Broadwind awarded $38M in wind tower orders - Broadwind announced that the Company has received $38 million in new tower orders from a leading global wind turbine manufacturer. Broadwind will manufacture the towers at its Abilene, Texas facility. The Company expects to complete production on the order in the first half of 2023.

07:22 EDT Kratos announces recent flight for family of Collaborative Combat Aircraft - Kratos Defense & Security Solutions announced another recent successful flight from its family of Collaborative Combat Aircraft-flying and demonstrating capabilities since 2015. Kratos' family of CCA's include more than four different aircraft types, with each having been flying for several years, proving, validating, and demonstrating key mission capabilities, as the DoD refines the ultimate range of requirements for the various CCA classes.

07:21 EDT Bitfarms says hashrate exceeds 4 EH/s milestone - Bitfarms hashrate exceeded the 4 exahash per second milestone as it commenced production at the first of two 50-megawatt warehouses under development in Argentina. The initial start-up adds 10 MW of capacity, increasing total corporate capacity to 176 MW. Throughout the remainder of Q3 2022 and during Q4 2022, the Company plans to light up additional 10 MW increments with a goal of the entire 50 MW being energized by December 31, 2022. In 2021, Bitfarms contracted with a private power company in Argentina to supply up to 210 MW to Bitfarms for warehouses being developed beside and on the same property as the generating facilities. For the first four-years, electrical costs are calculated based on a formula in which the cost of power is based on a combination of market-based pricing and at a base rate of US 2.2 cents per kilowatt. Following an initial start-up period and based on current foreign currency exchange rates and natural gas prices in Argentina, the cost of the power in Rio Cuarto is expected to be the lowest in Bitfarms portfolio, creating a significant advantage. Currently, Bitfarms operations in Argentina employs 28 team members, which is expected to increase as production is added.

07:20 EDT Xortx Therapeutics completes Pre-phase 3 meeting with FDA - XORTX Therapeutics is pleased to announce completion of the previously announced Type B Pre-phase 3 meeting with the US Food and Drug Administration held on September 16, 2022. In advance of this meeting, XORTX submitted a "Pre-Phase-3 Briefing Package" to the FDA on Thursday, July 28, 2022 and received responses from, and responded to the FDA prior to the meeting. To date, the Company has successfully completed numerous research and development activities leading to this meeting and is advancing its XRx-008 program for the treatment of autosomal dominant polycystic kidney disease. R&D activities during the past year leading to this meeting included manufacturing clinical quality GMP oxypurinol, finalizing formulation of drug product, and a number of non-clinical studies including the characterization of improved oral bioavailability of its proprietary formulation of oxypurinol in animal models. The Company has commenced the OXY-XRX-101 clinical pharmacokinetics study, reporting part 1 and 2 topline results from this study earlier this year. These key milestones and secondary pharmacokinetics modeling of the data from the Company's XRx-008 program well positioned XORTX for in-depth discussions during the Pre-Phase 3 meeting with the FDA. Prior to the meeting with the FDA, the Pre-Phase 3 Briefing Package provided an up-to-date summary of the extensive work completed for the XRx-008 program, including updates regarding chemistry, manufacturing, pharmacology, toxicology, clinical results to date, and regulatory and clinical plans. The FDA reviewed this package of data and accompanying questions to the agency and responded with minimal comments on the work accomplished to date and focused their feedback on XORTX clinical planning. As a result of minimal concerns by the FDA, the focus of the meeting was on optimizing trial design. Based on the discussion, XORTX believes it is well-position to complete a successful, single registration phase 3 clinical trial and associated considerations. Discussion during the meeting provided valuable guidance to the Company, and clarity on critical steps needed to achieve a successful clinical trial and marketing approval. A particularly valuable aspect of FDA advice was an emphasis on how the Company might gain market approval with a single phase 3 registration trial to demonstrate efficacy and safety. Following this meeting with the FDA, XORTX's plans for a single phase 3 registration trial remains the focus.

07:18 EDT H-CYTE enters LOI to acquire SkinDisc, terms not disclosed - H-CYTE entered into a letter of intent to acquire SkinDisc, a patent pending tissue regeneration technology, that is expected to close within the next 30 days. H-CYTE will submit a De Novo 510(k) pathway request for SkinDisc in the first half of 2023. SkinDisc maintains complete full wound contact and depth filling during the healing process, resulting in rapid growth of the host tissue from an active cellular matrix in a single application. The SkinDisc product has achieved healing in four to nine weeks, compared to current treatment approaches that require weekly applications and can take 12-20 weeks to heal, on average.

07:15 EDT Microbot Medical appoints Ripal Ghandi to scientific advisory board - Microbot Medical announced that Ripal Gandhi, MD, FSVM, will join the Company's robust Scientific Advisory Board. Dr. Gandhi is an interventional oncologist and a member of the Miami Cardiac & Vascular Institute and Miami Cancer Institute physician team where he specializes in minimally invasive treatments for peripheral vascular disease, cancer, and other diseases, and has a history of being an innovator in the Interventional Robotics field.

07:13 EDT Agios Pharmaceuticals appoints Cecilia Jones as CFO - Agios Pharmaceuticals (AGIO) announced the appointment of Cecilia Jones to the role of CFO, effective Sept. 26, 2022. Ms. Jones will replace Jonathan Biller, who served as the company's previous CFO and head of corporate affairs and who resigned effective Sept. 16, 2022 in order to become chief legal officer of Vertex Pharmaceuticals (VRTX). Jones joins Agios from LogicBio Therapeutics (LOGC), where she served as chief financial officer and was responsible for driving the company's financial strategy, including evaluation of financing alternatives and analysis of business development opportunities, and managing corporate financial planning, accounting, corporate communications and investor relations.

07:10 EDT Icanic Brands enters non-binding LOT to acquire The Leaf - Icanic Brands Company signed a non-binding Letter of Intent to acquire 100% of the equity interests in The Leaf at 73740, a premium California retailer located at 73740 El Paseo in Palm Desert, California. Under the terms of the LOI, the Company will acquire The Leaf for a purchase price that equates to 1.0x the trailing twelve months of The Leaf's revenue calculated on the date of closing. The purchase price will be payable in stock based on the 10 day volume weighted average price of the Company's common shares trading on the Canadian Securities Exchange. As part of the transaction, Icanic Brands will also be launching a new Direct To Consumer strategy for its portfolio of brands, including Real Deal Resin, Ganja Gold, Heady and Taylors. This DTC platform offers the convenience of online ordering with direct to your door delivery and unrivaled unboxing experience.

07:09 EDT Virios Therapeutics announces FORTRESS study did not meet primary endpoint - Virios Therapeutics announced results from its FORTRESS study of oral IMC-1 for the treatment of FM. Overall, the FORTRESS study did not achieve statistical significance on the prespecified primary efficacy endpoint of change from baseline to Week 14 in the weekly average of daily self-reported average pain severity scores comparing IMC-1 to placebo. However, analysis of the data suggests a bifurcation of response based on the timing of patient enrollment in the FORTRESS trial. During the first half of the trial, for the patients who were enrolled when the Delta variant of COVID-19 was the dominant strain in the U.S., IMC-1 demonstrated no improvement versus placebo-treated patients. Conversely, during the second half of the trial, for the patients who were enrolled when vaccination rates improved and the less severe Omicron variant of COVID-19 became the dominant U.S. strain, IMC-1-treated patients demonstrated a statistically significant improvement on the primary pain reduction endpoint at Week 14, as well as a statistically significant improvement in the key secondary PROMIS Fatigue assessment and the Fibromyalgia Impact Questionnaire-Revised symptoms domain score. IMC-1 was well-tolerated overall, with only 4.6% of IMC-1 treated patients dropping out due to adverse events, as compared with 8.1% of placebo treated patients. No adverse event category in the IMC-1 group exceeded a 4% rate with the exception of COVID-19 infection. Overall discontinuations were 18.5% in the IMC-1 treated group versus 23% in the placebo treated group. Patients in the FORTRESS trial were randomized one-to-one to either IMC-1 or placebo and patient background demographics and baseline pain scores were well matched.

07:08 EDT First Wave to direct near-term resources to new adrulipase formulation - CEO James Sapirstein said, "We are excited by the news announced last week concerning adrulipase, our product candidate for the treatment of exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis. As we announced, after extensive research by First Wave BioPharma and our drug delivery formulation partner, we believe we have identified an enhanced enteric microgranule drug delivery formulation of adrulipase for use in the continued development of our clinical program. We intend to submit an Investigational New Drug application to the U.S. Food & Drug Administration for a Phase 2 "proof-of-concept" clinical study investigating the improved formulation of adrulipase as a potential treatment for EPI. We anticipate that this trial will commence prior to year-end 2022, subject to FDA's acceptance of the IND. We believe the new formulation will allow us to reignite our adrulipase development program. For those new to First Wave BioPharma, adrulipase is our most clinically advanced asset and we believe it offers the potential to be a best-in-class treatment for EPI associated with CF and CP. The cumulative data generated in our earlier clinical trials of adrulipase demonstrated an excellent safety profile and a mechanism of action that we believe should enable a therapeutic benefit. However, as previously reported, the prior formulation resulted in an inconsistent dispersal of adrulipase in the gastrointestinal tract which resulted in it not achieving its efficacy endpoints. In our in vitro testing, the new enteric microgranule drug delivery formulation of adrulipase outperformed prior versions of the drug while enabling us to make significant improvements in manufacturing yields and lowering our costs. The in vitro data suggest the new formulation has a delayed-release profile that should protect adrulipase in the stomach and enable it to be delivered to the targeted areas of the GI tract where it can mix with food in the duodenum to provide its therapeutic effect. Based on our in vitro testing, we expect that the new formulation of adrulipase will result in consistent coefficient of fat absorption values greater than 80%. CFA greater than 80% is the recognized threshold for achieving therapeutic benefit in patients with EPI associated with CF and CP. Additionally, our research indicates that the enhanced formulation has the potential to significantly decrease the number of pills a patient would need to take to achieve the desired therapeutic effect. The pill burden associated with pancreatic enzyme replacement therapy can be as high as 40 capsules per day, creating a substantial challenge for EPI patients. We believe that a reduction in the number of pills required to maintain effectiveness will be a key differentiator for patients. Moreover, we have identified manufacturing improvements that we believe have the potential to lower the cost of goods by significantly increasing production yields. We are excited to present the research relating to this improved adrulipase formulation at AAPS 2022 PharmSci 360 in Boston next month. Given these important advances with adrulipase, we have made the strategic decision to direct our near-term resources towards the filing of the IND and the Phase 2 clinical trial of the new adrulipase formulation. As a result, we will be devoting fewer resources to our niclosamide programs following the mixed results from the COVID-19 trial and inconclusive data from a small Phase 2 trial of niclosamide in ulcerative proctitis and ulcerative proctosigmoiditis. We have also taken significant steps to improve our balance sheet, including settling the lawsuit filed against us by the former stockholders of First Wave Bio, Inc. on terms that included a significant restructuring of our obligations to them. The restructuring resulted in the elimination of approximately $10 million of fixed liabilities from our balance sheet. In compliance with our plan to regain and maintain compliance with Nasdaq's continued listing requirements, we effected a reverse stock split of our common stock in late August and have raised a significant amount of new capital since June 30, 2022, primarily through our at-the-market sales program, which is now complete. As part of our Nasdaq compliance plan, we hope to raise additional capital, subject to market conditions, to meet Nasdaq's continuing listing standards and to support our business."

07:05 EDT Bio-Techne issues 2022 Corporate Sustainability Report - Bio-Techne issued its 2022 Corporate Sustainability Report, CSR, detailing the progress advancing its Environmental, Social and Governance, ESG, initiatives. Bio-Techne's CSR is organized around four key pillars: People, Advancing Science, Governance and Operational Integrity, and The Environment. "At the end of fiscal 2022, Bio-Techne's global team has grown to approximately 3,000 employees... Our second pillar, Advancing Science, reflects our commitment to continuously innovate with an eye toward sustainability... We leverage this innovation to deliver the highest quality, most consistent products, while recognizing the impact these products have on society, the global and local economies in which we operate, as well as the environment...Our third pillar, Governance and Operational Integrity, highlights our approach to ethically operate and govern the business while ensuring financial and scientific integrity, data security and privacy, and risk management. In this latest CSR, we made significant progress with the level of disclosure surrounding our fourth pillar, The Environment. For the first time, we are including an inventory of our Scope I and Scope II greenhouse gas emissions data for our largest U.S. and European-based manufacturing facilities."

07:04 EDT H&E Equipment to acquire One Source Equipment Rental for $130M in cash - H&E Equipment Services, announced the signing of a definitive agreement to acquire One Source Equipment Rental a provider of non-residential construction and industrial equipment with operations in the Midwest and Southern U.S. One Source, which is employee owned, operates 10 branches, including three locations in each of Illinois and Indiana, two locations in Tennessee and one in each of Kentucky and Alabama. Under the terms of the definitive agreement, H&E is expected to pay $130M in cash for One Source, before customary adjustments. The transaction is expected to close during the fourth quarter of 2022, following regulatory clearance and the completion of other customary closing conditions. Brad Barber, Chief Executive Officer of H&E Equipment Services, , noted the excellent strategic rationale for the transaction, stating, "For more than 20 years, One Source has emphasized a culture where equipment reliability and customer support and satisfaction are vital features for success, resulting in an equipment rental operation with strong consumer loyalty throughout its branch network. These important attributes, which are underscored by a dedicated base of employee owners, offer an exceptional cultural fit with H&E. Also, the transaction will expand our geographic footprint into the Midwest with operations in Illinois and Indiana, as well as operations in Kentucky. Finally, the demonstrated success of our accelerated warm start plan, with 15 warm start and greenfield locations established since early 2021, will prove beneficial as we evaluate post-integration growth opportunities in the Midwest and other surrounding regions with attractive prospects for expansion." Over the last twelve months ended July 31 One Source has generated revenues of approximately $59 million with a fleet size, as measured by original equipment cost , of approximately $138M. One Source's fleet consists primarily of aerial work platforms, material handling equipment and other general equipment lines. Following the closing of the transaction, H&E's equipment rental operations will extend across 117 branch locations in 28 states.

07:01 EDT AutoZone opened 118 new stores in the U.S. in 2022 - During the fiscal year ended August 27, 2022, AutoZone opened 118 new stores and closed one in the U.S., opened 39 stores in Mexico and 20 stores in Brazil. As of August 27, 2022, the Company had 6,168 stores in the U.S., 703 in Mexico and 72 in Brazil for a total store count of 6,943.

06:56 EDT Northern Dynasty highlights design features of Pebbles tailings storage facility - Northern Dynasty Minerals and the Pebble Partnership highlight several design features that enhance the safety of the tailings storage facility for the Proposed Pebble Project to counter negative generalizations repeatedly put forward by project opponents. "The failure of a tailings storage facility around the world is rare. When one does occur, however, failure is often caused by the accumulation of too much water," said Ron Thiessen, President and CEO of Northern Dynasty. "The tailings storage and management plan for Pebble includes an investment of approximately $500 million in modern water treatment facilities to allow the water to be treated and safely released into the environment, meeting all required standards, instead of accumulated. Because of this and other design features, such as constructing the embankments on bedrock and with flatter slopes than is typical in the industry, the Army Corps of Engineers in the 2020 Environmental Impact Statement said that they could not conceive of how a failure could occur. The fact is that Alaska has a very rigorous dam permitting process which will ensure that the facility will be safe before it is built. We invested a further $150 million in studies of the climate and potential for earthquakes in the area, conducted by a team of industry experts to ensure that the TSF would be safe. Our studies and the research and reports out of the United States Geological Survey demonstrate that Pebble isn't a high seismicity area, as most earthquakes in this region of Alaska are offshore and are almost abated by the time they reach the north shore of Lake Iliamna/Pebble. Still our approach to seismicity was to ensure the facilities can withstand the likely earthquake events that might impact SW Alaska, including a repeat of the 1964 Valdez 9.2 M earthquake. This was the largest event ever recorded in North America and the second largest ever," Mr. Thiessen added. More than 30 alternative tailings sites were evaluated before the final site was selected to minimize the tailings footprint on wetlands. In fact, our project as proposed would impact less than one mile of stream for every 1,000 miles of streams feeding into Bristol Bay.

06:53 EDT 23andMe appoints Daniel Chu as CPO - 23andMe Holding (ME) appointed Daniel Chu as Chief Product Officer. Prior to joining 23andMe, Chu served as Chief Product Officer for Waymo (GOOG, GOOGL).

06:50 EDT Cingulate presents data from formulation study of CTx-2103 - Cingulate announced findings from its formulation study for CTx-2103, the Company's asset for the management of anxiety-related disorders. The data was featured in a poster presentation at the 2022 Psych Congress meeting, taking place September 17-20 in New Orleans, LA. In the study, the pharmacokinetics were evaluated for three multi-layered, timed-release oral tablets and one immediate release dose of buspirone. Scintigraphic imaging visualized transit of the tablets through the gastrointestinal tract to confirm both the site and onset of release, which will then be correlated with pharmacokinetic data to establish the full release profile of the CTx-2103 formulation. Anxiety disorders are the most common mental health concern in the U.S.1 An estimated 31 percent of U.S. adults experience an anxiety disorder at some time in their lives. People may live with anxiety for years before they are diagnosed or treated. CTx-2103, which contains the active pharmaceutical ingredient buspirone hydrochloride, a non-benzodiazepine medication, has no evidence for the development or risk of dependency. However, due to its short half-life, buspirone is prescribed to be taken several times a day for management of anxiety, which can be challenging for patients and may lead to sub-optimal treatment outcomes. CTx-2103 will be designed as a once-daily, multi-dose tablet, which the Company believes will offer clear differentiation and compelling advantages over currently available treatment options.

06:48 EDT Pfizer announcs top-line results from Phase 3 study of 20vPnC - Pfizer today announced top-line results from its pivotal E.U. Phase 3 study in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate for the prevention of invasive pneumococcal disease, pneumonia, and acute otitis media caused by the 20 Streptococcus pneumoniae serotypes contained in the vaccine for the pediatric population. The study had three coprimary outcomes, associated with immunogenicity responses one month after the second and third doses of a three-dose vaccination series given at approximately 2, 4, and 11-12 months of age of 20vPnC compared to Prevenar 13. For the non-inferiority co-primary objective of immunoglobulin G geometric mean concentrations one month after Dose 3 at 11-12 months of age, 19 of the 20 serotypes met the NI criteria with only one serotype narrowly missing. For the NI co-primary objective of IgG GMCs one month after Dose 2, 16 of the 20 serotypes met NI. Finally, for the third NI co-primary objective of the percentage of participants with predefined serotype-specific IgG concentrations one month after Dose 2, nine of the 20 serotypes met the NI criteria. All 20 serotypes showed increased booster responses from post dose 2 to post dose 3 which are indicative of immunological memory and long-term protection. All 20 vaccine serotypes also showed strong functional antibody responses as measured by the opsonophagocytic assay post-dose 2 and post dose 3 similar to Prevenar and Prevenar 13. The totality of data is therefore directionally consistent with prior clinical experience with Prevenar and Prevenar 13 after 2 and 3 infant doses, both of which have demonstrated effectiveness in a three-dose schedule against the serotypes contained in the vaccine in post-licensure studies. In summary, the totality of these 20vPnC data, combined with the experience with Prevenar 13 in this schedule, demonstrates that the 20vPnC candidate, if approved, is likely to help protect against all 20 vaccine serotypes in a three-dose vaccine series. The safety profile of 20vPnC was similar to Prevenar 13 in this schedule, and concomitant use with common pediatric vaccines were supported. Pfizer plans to file these data by the end of this year with the European Medicines Agency. These positive data mark the conclusion of pivotal topline readouts for the 20vPnC pediatric program. Pfizer will also seek to present and publish outcomes from this clinical trial at a future date once safety and immunogenicity data have been fully analyzed.

06:43 EDT First Solar, Azure Power enter agreement for 600 MW of PV solar modules - First Solar (FSLR) announced that it has entered into an agreement to supply 600 megawatts DC of its high-performance, advanced thin film photovoltaic solar modules to Azure Power Global Limited (AZRE). The agreement is the first for production from First Solar's new manufacturing facility in Tamil Nadu, India, which is expected to be commissioned in the second half of 2023. Under the agreement, Azure is expected to take delivery of First Solar's Series 7 photovoltaic solar modules from the fourth quarter of 2023 to 2025.

06:40 EDT Novartis' Sandoz reports on denosumab integrated Phase I/III clinical trial - Sandoz announces the release of "positive" results from the integrated ROSALIA Phase I/III clinical trial study for its proposed biosimilar denosumab. "Denosumab is indicated for treating a variety of conditions, including osteoporosis in postmenopausal women, in men at increased risk of fractures, treatment-induced bone loss, prevention of skeletal related complications in cancer that has spread to the bone, and giant cell tumor of the bone. The results from the integrated Phase I/III study confirm the biosimilar matches the reference medicine in terms of pharmacokinetics, pharmacodynamics, efficacy, safety and immunogenicity in the respective indications; and contributes to demonstration of similarity, which is the basis for use in all indications," the company stated. "The results come soon after Sandoz confirmed acceptance of license applications for two other proposed biosimilars. In July 2022, the application for the first-of-a-kind multiple sclerosis proposed biosimilar natalizumab was accepted for review by the US Food and Drug Administration and European Medicines Agency. In June 2022, the EMA and FDA accepted for review Sandoz applications for the high-concentration formulation 100 mg/mL of its biosimilar adalimumab," the company added.

06:37 EDT FOXO Technologies completes business combination with Delwinds Insurance - On Frida, the company announced: "FOXO Technologies announced the completion of its business combination with Delwinds Insurance Acquisition Corp. (DWIN) , a publicly traded special purpose acquisition company. The products and services FOXO is developing combine longevity science with life insurance to: (i) support consumer health and wellness engagement, and (ii) simplify the consumer underwriting journey. The combined company will operate under the name "FOXO Technologies Inc.," and will be led by Chief Executive Officer Jon Sabes. Commencing at the open of trading on September 16, 2022, FOXO's Class A common stock are expected to trade on the NYSE American exchange under the symbol "FOXO". FOXO's warrants will continue to trade on the NYSE exchange under the symbol "FOXO WS", and it is anticipated that trading of the warrants will move to the NYSE American exchange shortly. Upon the consummation of the Business Combination, each outstanding unit of Delwinds was automatically separated into one share of Delwinds Class A common stock and one half of one Delwinds warrant and each share of Delwinds class A common stock and each whole warrant of Delwinds was exchanged for one FOXO common share and one FOXO warrant, exercisable into shares of FOXO Class A common stock, respectively. The warrant exercise price for each FOXO warrant is $11.50."

06:37 EDT BitNile sees mining production run rate of 4.7 BTC per day by September end - BitNile Holdings provided projections on expected Bitcoin mining production levels. The Company expects to have 7,500 miners at its Michigan data center and 6,500 miners at the Texas facility hosted by Computer North, LLC installed by the end of September 2022. This includes the 2,004 S19j Pro Antminers that had been held by U.S. Customs and Border Patrol for review and audit, which miners have been released and delivered to the Company's Michigan property. Based on expected installations of S19j Pro and S19 XP Antminers, BitNile expects to increase its average daily mining production to approximately 4.7 Bitcoin per day by the end of September 2022, nearly doubling to approximately 9.33 Bitcoin per day by the end of December 2022, based on current market conditions, including a mining difficulty of 32.05 trillion. As previously disclosed, BitNile has entered into purchase agreements with Bitmain Technologies Limited for a total of 21,925 Bitcoin miners, including 4,600 environmentally friendly S19 XP Antminers that feature a processing power of 140 terahashes per second and 17,325 S19j Pro Antminers that feature a processing power of 100 TH/s. Once all of the miners are fully deployed and operational, BitNile expects to achieve a mining production capacity of approximately 2.3725 exahashes per second.

06:31 EDT Kaman completes acquisition of Parker-Hannifin Aircraft Wheel & Brake Division - Kaman Corporation (KAMN) announced that it completed the acquisition of the Parker-Hannifin Corporation (PH) Aircraft Wheel & Brake Division on September 16, 2022. Aircraft Wheel & Brake has been a trusted provider of mission-critical wheel and brake technology products and solutions for more than 80 years. With a strong OEM and aftermarket portfolio supporting more than 100 platforms, Aircraft Wheel & Brake specializes in wheels, brakes and related hydraulic components for helicopters, fixed-wing and UAV aircraft. They have long-standing global relationships with leading military and general aviation customers providing customized proprietary designs, protected by intellectual property. Aircraft Wheel & Brake operates out of one centralized facility in Avon, Ohio, providing a full suite of capabilities including design, development and qualification, as well as manufacturing, assembly, product support and repairs.

06:11 EDT Puyi appoints CEO Yong Ren as chairman of the board - Puyi announced that, with immediate effect, Yong Ren, CEO of the Company, has been appointed by the Company's board of directors as chairman of the Board, filling the vacancy left by the resignation of Haifeng Yu, the former chairman of the Board. As of today, the Board has six directors, including three independent directors

06:09 EDT Rubicon Organics expects to be operating cashflow positive in 2022 - Rubicon Organics provides a corporate and operational update for the period ending August 31, 2022. The company said, "The Company is pleased to reiterate its financial guidance from August 15, 2022 with its current expectation to be operating cashflow positive and Adjusted EBITDA profitable in fiscal 2022. As previously reported, the Company achieved positive Adjusted EBITDA in the three months ended June 30, 2022. We believe that our increased product quality and brand portfolio has positioned Rubicon to deliver on its commitments and win in the premium cannabis market in Canada. In addition, the Board of Directors of the Company has now begun its search of internal and external candidates for a Chief Executive Officer successor who can lead the Company in driving forward its vision to be the global brand leader in premium organic cannabis. The Company's fully licensed 125,000 sq. ft. glass-roofed facility in Delta, BC has been successfully connected to the BC Hydro power grid. This power grid connection to the Delta Facility eliminates the need for the daily operation of natural gas generators, reduces the Company's operating costs and further contributes to one of our Environmental, Social and Governance goals to reduce greenhouse gas emissions. The Company is in the process of purchasing a backup generator capable of supporting all key operational systems in the event of a power outage. For the three months ending August 31, 2022, the Company achieved total market share of 8.6%2 in the premium flower and pre-roll category across Canada. In 2022, we have now consistently seen our average THC increase significantly, with certain strains as high as 29% THC. We believe that our quality step change in market since the spring has been experienced by our consumers and has led to the strong rate of sales and resulting increase in revenue. Our priority and focus remains delivering super-premium quality cannabis flower and pre-rolls as the key pillar of Rubicon's business."

05:28 EDT Biohaven Pharmaceutical sets record date for spin-off - Biohaven Pharmaceutical announced that it has set a record date of September 26 for the previously announced spin-off by Biohaven of its Biohaven subsidiary, which will own the Kv7 ion channel activators, glutamate modulation, myeloperoxidase inhibition and myostatin inhibition platforms, preclinical product candidates, and certain corporate infrastructure currently owned by Biohaven. The completion of the spin-off remains subject to closing conditions noted in Biohaven's Proxy Statement filed on August 30, including receipt of shareholder approval at Biohaven's special meeting of shareholders to be held on September 29. Beginning on September 23 and continuing until the occurrence of the distribution on the Distribution Date, Biohaven common shares will trade with an entitlement to the distribution under the symbol (BHVN). Any holders of Biohaven common shares who sell shares on or before the distribution date will also be selling their right to receive SpinCo common shares. Investors are encouraged to consult with their financial advisors regarding the specific implications of buying or selling Biohaven common shares on or before the distribution date.

05:23 EDT Ballard Power announces minority investment in Quantron AG - Ballard Power announced a minority equity investment in Quantron AG, a global electric vehicle integrator and an emerging specialty OEM, to accelerate fuel cell truck adoption. As part of Quantron's financing round of up to 50M euros, Ballard's investment proceeds will be used by Quantron to develop their truck fuel cell vehicle platforms, under the terms of a joint development agreement. Ballard will be the exclusive fuel cell supplier to Quantron for these platforms. As part of the strategic partnership, Quantron committed to purchase 140 FCmove modules totaling approximately 17MW, with an option to purchase an additional 50 units. The fuel cell modules are expected to be delivered in 2023 and 2024. The zero-emission fuel cell electric vehicle platforms developed by Quantron will integrate Ballard fuel cell products for various truck applications in Europe and the U.S. Quantron's initial market focus is Germany, where their new 44T fuel cell truck is to be unveiled at IAA Transportation 2022.

05:17 EDT AbbVie announces CHMP opinion recommending approval of risankizumab - AbbVie announced the European Medicines Agency's, or EMA, Committee for Medicinal Products for Human Use, or CMHP, adopted an opinion recommending the approval of risankizumab for the treatment of adults with moderately to severely active Crohn's disease who have had inadequate response, lost response or were intolerant to conventional or biologic therapy. Risankizumab is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally.

05:10 EDT UP Fintech announces TradeUP Securities becomes member of NYSE - UP Fintech announced that its subsidiary TradeUP Securities is the latest member of the New York Stock Exchange, or NYSE. The NYSE's approval gives the company membership in New York Stock Exchange, NYSE American, and NYSE Arca, respectively, making it one of the very first fintech brokers to obtain this status. The move also boosts its worldwide number of global licenses and qualifications from 56 to 59. The membership enables UP Fintech, also known as Tiger Brokers, to offer investors direct access to rapid and electronic executions on NYSE, in an upgraded investing experience reshaped by lower latency, more competitive pricing, and more flexible order placements. The approval comes after an all-around assessment by NYSE over UP Fintech's compliance standards, operations management, capital requirements, and its front- and back-end systems.